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Background: The human cytosolic thioredoxin (Trx) contains a redox-active dithiol moiety in its conserved active-site
sequence. Activation by a wide variety of stimuli leads to secretion of this cytoplasmic protein. Function of Trx1 has
been implicated in regulating cell proliferation, differentiation, and apoptosis. The aim of this study was to assess the
clinical significance of serum Trx1 level in patients with breast carcinoma.
Results: To clarify whether serum levels of Trx1 could be a serum marker for breast carcinoma, we measured the
serum levels of Trx1 in patients with various carcinomas (breast, lung, colorectal, and kidney cancers) using an
ELISA, and investigated its associations with the tumour grading from I to III. At the cut-off point 33.1725 ng/ml
on the receiver operating characteristic curve (ROC) Trx1 could well discriminate breast carcinoma from normal
controls with a sensitivity of 89.8%, specificity 78.0%, and area under the ROC (AUC) 0.901 ± 0.0252. The serum
level was well correlated with the progress of the breast carcinoma. We also investigated the diagnostic capacity
of CEA and CA15-3 for the early detection of metastatic breast cancer comparing that of Trx1. In contrast to the
serum CEA and CA15-3 tumour markers, the serum Trx1 levels of the early cancer (grade I) patients were significantly
higher than those of normal control subjects, showing a high diagnostic sensitivity and selectivity (89.4% sensitivity, and
72.0% specificity). The serum levels of Trx1 in various patients with lung, colorectal, and kidney carcinomas indicate that
the level of Trx1 is significantly higher than those of other cancer patients. Combinational analysis of CEA or CA15-3 with
Trx1 for the detection of breast cancer suggest that the diagnostic capacity of CEA or CA15-3 alone for the early
detection of breast cancer, especially regarding sensitivity, is significantly improved by its combination with Trx1.
Conclusions: Taken together, we conclude that serum Trx1 is useful for the early diagnosis of breast cancer or the
early prediction prognosis of breast cancer, and therefore has a valuable use as a diagnostic marker and companion
marker to CEA and CA15-3 for breast cancer.
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Organisms living under aerobic conditions are exposed
to reactive oxygen species (ROS) such as superoxide
anion (O2
–), hydrogen peroxide (H2O2), and nitric oxide
(NO), which are generated by redox metabolism, mainly
in mitochondria. It has been demonstrated in vitro that
ROS in small amounts participate in many physiological
processes such as signal transduction, cell differentiation,
apoptosis, and modulation of transcription factors [1-4].
All organisms, from prokaryotes to primates, are equipped
with different defensive systems to combat the toxic pro-
cesses of ROS. Regulation mechanisms of ROS play a cru-
cial role in tumour development. Transformed cells are
known to generate more ROS than normal cells [5,6].
ROS not only contribute to tumor progression by amplify-
ing genomic instability but also transformed cells use ROS
signals to sustain proliferation [5].
Thioredoxin (Trx) is a 12-kDa oxidoreductase that is
kept in the reduced state by thioredoxin reductase in a
NADPH-dependent reaction. Serving as a general disul-
fide oxidoreductase, thioredoxin facilitates the reduction
of other proteins by a redox mechanism based on re-
versible reduction of a disulfide to two cysteine thiol
groups, thereby recovering the normal function of the
proteins. Trx1 as an antioxidant protein is induced by
various kinds of oxidative stresses [7-10]. In mammalian
cells, Trx1 is also involved in the regulation of ROS
levels and thus in cell death. In addition to its critical
role in the regulation of cellular redox homeostasis,
Trx1 has multiple actions in the cell. Therefore, Trx1 is
potentially important in conjunction with the onset of
many diseases including inflammatory diseases, heart
failure, cancer, etc. Trx1 plays an important role in regu-
lating cancer cell growth, for example, by modulating
the DNA binding activity of transcription factors, includ-
ing nuclear factor-κB, p53, and glucocorticoid and estro-
gen receptors [11-16]. Immunohistochemical analysis with
anti-Trx1 antibodies revealed the expression of Trx1 in
cancer cells in various tissues such as the liver, colon, pan-
creas, and the uterine cervix, indicating the implication of
Trx1 in oncogenesis [17-19].
Breast cancer is reported to occur at a higher rate in
women of advanced countries than do other cancers
[20]. The incidence of breast cancer and the mortality
from breast cancer in low-developed countries are ex-
pected to increase for a significant period of time in the
future in consideration of the trend of because of the
westernization of living. As they grow, breast cancer
cells, like other cancer cells, generally infiltrate adjacent
tissues or metastasize into the lymph nodes. In most
breast cancer cases, the patients did not have many de-
tectable symptoms or they did not examine their breasts
by themselves. Therefore, it is very important to effect-
ively diagnose early breast cancer to reduce mortalityfrom breast cancer. To decrease the mortality from
breast cancer, early diagnosis is the most important
thing. It is also important to do an adjuvant therapy that
is suitable in light of the prognosis after the primary ini-
tial treatment. For the diagnosis of breast cancer, various
methods are used in combination. To supplement such
breast screening methods, attempts have been made to
use blood tumor marker levels to diagnose breast cancer.
Although studied for their values as diagnosis or progno-
sis factors, the application of conventional tumor markers
is accompanied by limitations, and there are no officially
recommended breast cancer markers.
There has been a need for a diagnostic marker and a
method for breast cancer that allows the accurate diagno-
sis of early breast cancer and allows the prognosis of
breast cancer to be made. Almost few studies have been
done on the use of Trx1 as a diagnostic marker for breast
cancer. Recently, we reported that Trx1 are overexpressed
in human breast carcinoma tissues and the expression
levels are associated with tumor grade [21]. Found to be
overexpressed in human breast cancer tissues, Trx1 allows
the diagnosis and prognosis of breast cancer and thus is
useful as a diagnostic marker for breast cancer. The strik-
ing induction of Trx1 in breast cancer tissues may enable
their use as a blood diagnostic marker for breast cancer.
Intensive and thorough research into the simple and
selective diagnosis of breast cancer using blood, which is
a relatively easily obtainable specimen, resulted in the
finding that healthy persons and patients affected with
breast cancer exhibit different plasma levels of Trx1.
Trx1 can be used as a diagnostic marker for breast can-
cer, which is characterized by a remarkable, highly spe-
cific, and sensitive elevation of the serum Trx level.
Methods
Subjects
All clinical grade sera of normal persons (control) and
various cancer patients were obtained from two global
supplier of human samples, Asterand (http://www.aster
and.com) and Bioserve (http://www.bioserve.com). All the
sera and the clinical information were provided from the
global supplier as summarized in Table 1. All samples were
collected from their collaborating clinical sites with full ad-
herence to proper informed consent, as well as their strict
institutional review board (IRB) and Health Insurance
Portability and Accountability Act (HIPAA) compliance.
To make them suitable for a biomarker study, all the sera
were collected and treated according to the instructions of
the FDA (Food and Drug Administration) and the NCI
(National Cancer Institute).
Assay for Trx1 protein
An indirect ELISA (Enzyme-linked immunosorbent
assay) was performed to quantitatively analyze the level of
Table 1 Clinical information of serum of normal control and patients with various cancers
Breast carcinoma Non-small Cell Lung Cancer (NSCLC) Colorectal carcinoma Kidney carcinoma Normal control
Characteristics Characteristics Characteristics Characteristics Characteristics
No. of samples 197 No. of samples 111 No. of samples 64 (Rectal 14) No. of samples 30 No. of samples 100
Female 197 Male 50 Male 33 (Rectal 7) Male 17 Male 50
Mean age (years) 48.54 ± 18.43
(20–91)
Female 61 Female 31 (Rectal 7) Female 13 Female 50
Stage I 66 (35:31)* Mean age (years) 41 ± 10.39
(41–85)
Mean age (years) 63.84 ± 12.20
(39–78)
Mean age (years) 55.07 ± 11.22
(34–76)
Male mean age (years) 44.54 ± 14.85
(20–76)
Stage II 70 (37:33) Stage I 39 (IA 19, IB 20) Stage I 6 Stage I 26 Female mean age (years) 43.70 ± 14.95
(18–71)
Stage III 61 (34–27) Stage II 32 (IIA 16, IIB 16) Stage II 36 (Rectal 7) Stage II 4 Female/Male 44.12 ± 14.83
Lobular type 106 Stage III 30 (IIIA 21, IIIB 90) Stage III 22 (Rectal 7) Mean age (years) (18–76)
Ductal type 91 Stage IV 10
All sera obtained from Caucasian White.
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tion of blood samples taken from normal persons and
breast cancer patients were used for quantitative protein
analysis with an indirect ELISA kit using antibodies of
Trx1 (Express ELISA kit for rabbit, GenScript). In this re-
gard, rabbit polyclonal antibodies to respective antigens
were obtained by injecting purified human Trx1 into rab-
bits to form antisera and purifying the antisera on a Pro-
tein A column. After the pre-coated antibody in a 96-well
plate is allowed to react with the antigen, the antigen-
antibody complex is treated with the secondary antibody
conjugate, followed by immobilizing and washing 3 times
with the washing solution. TMB (3,3′,5,5′-tetramethyl
benzidine) was used as the substrate, and a sulfuric acid
solution (2 M sulfuric acid) was used to stop the enzym-
atic reaction. The sandwich ELISA kits for CEA and
CA15-3 from Abcom (Cambridge, MA, USA), were used
to measure serum CEA and CA15-3 protein levels per the
manufacturer’s instructions.
A standard curve was made from the absorbance at
450 nm of various concentrations of each protein. Serum
protein levels were determined with reference to the
standard curve from the mean values of three measure-
ments of absorbance at 450 nm.
Statistical analysis
For statistical analysis, the GraphPad Prism software
(ver. 5.04) and MedCal statistical software (ver. 12. 4. 0. 0)
were used for statistical analysis. We used the Pearson cor-
relation to test for associations between different variables.
The t test and one-way ANOVA were performed to calcu-
late the P value. The P values were considered statistically
significant if P < 0.05.
Results
Measurement of Serum Trx1 level in normal persons
The serum levels of Trx1 in different normal individuals
were analyzed by an ELISA. The measurements were
performed on the sera of 50 normal female and male per-
sons over a wide range of ages (20 – 76 for male, 18 – 71
for female) with a uniform distribution (44.54 ± 14.85 for
male, 43.70 ± 14.95 for male, and 44.12 ± 14.83 for fe-
male/male; mean ± SD) (Table 1). The individual data
were depicted as a function of age in Figure 1 and the
statistics were summarized in Table 2. As shown in
Table 2, the mean value of serum Trx1 levels were de-
tected at 27.24 ± 6.155, 28.62 ± 6.054, 27.93 ± 6.113 (SD)
ng/mL for male (NM), female (NF), and female/male
(NFM), respectively. The plot shown Figure 1 indicates
that the serum levels appear to be slightly elevated as
the function of age for male (Figure 1A), and female
(Figure 1B) normal controls, but they showed no statistical
significance (P = 0.2136 for male controls, P = 0.0848 for
female controls).Measurement of serum Trx1 level in patients with breast
cancer and other cancers
Trx1 levels in serum samples obtained from patients
with breast cancer (BC), lung cancer (LC), kidney cancer
(KC) and colorectal cancer (CRC) were assayed using
ELISA, and the results were displayed as a scatter dot
plot (Figure 2). The statistics were summarized in Table 2.
As can be seen in Figure 2, serum Trx1 levels were
higher in the breast cancer group than in other cancer
patients as well as in the female normal control (NF)
and male normal control (NM), with statistical signifi-
cance. Further, as shown in Table 2, the blood of breast
cancer patients retained significantly higher levels of
Trx1 than did that of other cancer patients. The mean
value of serum Trx1 levels was detected at 40.12 ±
6.816 ng/mL in the breast cancer group (BC), with about
a 40.2% increase compared to the normal female control.
With reference to the serum level of Trx1 according to
sub-type of breast cancer, it was 40.03 ± 6.793 ng/mL in
lobular carcinoma of breast (BCL) and 40.22 ± 6.878 ng/mL
in ductal carcinoma of breast (BCD). The serum Trx1 level
in lobular carcinoma of breast was nearly same as that in
ductal carcinoma of breast.
The Trx1 level in lung (LC), colorectal (CRC), and kid-
ney (KC) were detected at 37.71 ± 8.254, 32.92 ± 7.864,
and 31.12 ± 7.541 ng/mL, with about a 13.5%, 17.9%, and
10.7% increase, respectively, compared to the female/
male normal control (NFM). The differences among the
levels of LC, CRC, and KC are not statistically significant
(P > 0.05), but the differences between BC and other
cancers are significant (P < 0.0001).
In addition, measurements of serum Trx1 levels in the
female normal control (n = 50) and the breast (n = 197)
and other cancer groups (n = 111 for non-small cell lung
cancer, n = 64 for CRC, and n = 30 for KC) were sub-
jected to ROC curve analysis, and the results are sum-
marized in Table 3.
As can be seen in Table 3, when compared to the fe-
male normal control (NF, n = 50) and the male normal
control (NM, n = 50), the AUC (area under curve) value
was measured at 0.911 ± 0.0179, and the cut-off value
at >32.3390 ng/mL, with a sensitivity of 89.3% and a
specificity of 78.0%.
Taken together with the parameters from ROC analysis
on the serum Trx1 levels of various cancer patients sum-
marized in Table 3, this data indicates that Trx1 can be
used as a breast cancer marker capable of discriminating
breast cancer patients from the female control at higher
probability with superior sensitivity and specificity.
Analysis of Trx1 as breast cancer-specific marker
To examine the selectivity of the blood marker Trx1 for
breast cancer, the data of serum Trx1 levels for breast
cancer in comparison to other cancers of shown in Figure 2
Figure 1 Serum levels of Trx1 in normal male and female controls as a function of age. Clinical information for each healthy person was
provided by the supplier. The individual values of male (A) and female (B) normal controls are the average values of three measurements.
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cer (CRC) was subjected to ROC curve analysis, and the
results are shown in Table 4.
As is understood from the data of Figure 2, Tables 3
and 4, serum Trx1 levels were significantly higher in the
breast cancer group than in other cancer patient groups
as well as in the female and male normal control (NFM).
In addition, when the serum Trx1 level was measured in
breast cancer patients in comparison with other cancer
patients, the AUC (area under curve) value exceeded
about 0.75, with the sensitivity and selectivity detected at
more than 75% and 55%, respectively, in all cases, indi-
cating that Trx1 is useful as a breast cancer-specific
marker.
Sensitivity of Trx1 with the progress of cancer
In order to reexamine the selectivity of Trx1 as a breast
cancer-specific marker and to confirm the proportional
correlation of serum Trx1 level with the progress ofTable 2 Statistics for serum Trx1 levels of normal controls an
Normal (N) Control
NF NM NFM I-III I
# of values 50 50 100 197 66
Minimum 14.99 15.61 14.99 26.19 26.19
25% Percentile 23.98 22.35 23.26 35.53 32.99
Median 28.5 26.22 27.64 38.98 36
75% Percentile 32.04 31.97 31.96 44.77 39.08
Maximum 42.78 42.22 42.78 60.01 48.07
Mean 28.62 27.24 27.93 40.12 35.93
Std. Deviation 6.054 6.155 6.113 6.816 4.346
Std. Error 0.8561 0.8705 0.6113 0.4856 0.5349
Lower 95% CI 26.9 25.49 26.72 39.16 34.86
Upper 95% CI 30.34 28.99 29.14 41.08 36.99
*Abbreviation used: F; Female, M; Male, BC; Breast Cancer, L; lobular carcinoma of br
colorectal cancer, KC; kidney cancer, CI; confidential interval.breast cancer, a comparison was made with blood sam-
ples taken from many lung cancer patients (LC). The re-
sults are shown in Figure 3.
As shown in Figure 3, the serum Trx1 level exhibited
a correlation with the progress of breast cancer in a pat-
tern similar to that shown in the progress of lung
cancer.
These data indicate that the increase of serum Trx1
level with the progress of cancer is due to the oxidative
stress increased with the progress of cancer. However,
the serum Trx1 level in the lung cancer group was about
21% lower than that in the breast cancer group, suggest-
ing that the high increase in the breast cancer group is
attributed to the specificity of Trx1 for breast cancer.
Comparison of Trx1 with carcinoembryonic antigen (CEA)
as a breast cancer marker
It was found that serum from individuals with various
carcinomas including breast carcinoma had higher levelsd various cancer patients





(I/II)II III L D
70 61 106 91 111 63 30
28.51 28.45 26.19 29.35 13.22 14.77 28.51
35.9 39.45 35.82 34.91 25.23 27.71 25.79
38.97 43.98 39.03 38.98 31.89 31.09 30.96
44.74 50.45 44.72 44.94 37.84 38.29 35.54
53.37 60.01 56.64 60.01 50 55.02 46.11
40.1 44.67 40.03 40.22 31.71 32.92 31.12
6.15 6.882 6.793 6.878 8.254 7.864 7.541
0.7351 0.8812 0.6598 0.721 0.7835 0.9908 1.377
38.63 42.91 38.72 38.79 30.16 30.94 28.31
41.57 46.43 41.34 41.65 33.26 34.9 33.94
east cancer, D; ductal carcinoma of breast cancer, LC; lung cancer, CRC;
Figure 2 Serum Trx1 levels in the breast cancer group and
other cancer groups (kidney cancer, lung cancer and colorectal
cancer). Clinicopathological information for each patient was
provided by the supplier. The individual mean value (n = 3) was
depicted as a scatter plot. The median value of each group is
depicted by horizontal lines, and the interquartile range is displayed
by vertical lines extending to the up and down of the median.
Abbreviations: BC, breast cancer; KC, kidney cancer; LC, lung cancer;
CRC, colorectal cancer; NM, male normal control; NF, female normal
control; NFM, female and male normal controls.
Table 3 Parameters from ROC analysis on serum Trx1 levels i
Type of cancer AUC* (±SEM) Sensitivity (%) S
Breast/NFM 0.911 ± 0.179 89.3
Colorectal/NFM 0.687 ± 0.0425 68.3
Kidney/NFM 0.633 ± 0.0617 46.7
Lung/NFM 0.643 ± 0.0381 54.1
Normal Control - -
*P < 0.0001.
Table 4 Parameters from ROC analysis on serum Trx1
levels between patients with breast and other cancers
Type of
cancer
AUC* (±SEM) Sensitivity (%) Specificity (%) Criterion
(ng/ml)
BC/NMF 0.911 ± 0.0179 89.3 78.0 >32.3390
BC/CRC 0.765 ± 0.0388 88.8 58.7 >33.5024
BC/KC 0.809 ± 0.0461 75.6 76.7 >35.3212
BC/LC 0.773 ± 0.0281 89.3 55.0 >32.2963
*P < 0.0001.
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as a breast cancer marker. Therefore, we investigated the
diagnostic capacity of Trx1 and CEA for the detection of
breast cancer comparing the parameters from ROC
curve analysis.
As depicted in Figure 4, increased serum levels of
Trx1 and CEA were detected in breast cancer patients,
but the increase of CEA levels (10%, from 7.731 ± 1.051
to 8.525 ± 1.282 ng/mL: mean ± SD) was significantly
lower than that of Trx1 levels (56.8%, from 25.59 ± 4.211
to 40.12 ± 6.816 ng/mL: mean ± SD) compared to their
values of corresponding female normal controls. Further,
the both serum levels were observed to have a propor-
tional correlation with the progress of breast cancer, with
statistical significance, however the serum Trx1 level ex-
hibited a superior correlation with the progress of
breast cancer (P < 0.0001) compared to CEA (P < 0.05).
To examine the superiority of Trx1 as a blood marker
for breast cancer, the data of serum Trx1 and CEA levels
for breast cancer were subjected to ROC curve analysis,
and the results are shown in Table 5. As shown in
Table 5, the AUC value for Trx1 exceeded about 0.83,
with the sensitivity and selectivity detected at more than
82% and 72%, respectively, in all the cancer grades from
I to III. In case of CEA, as shown in Table 4, when com-
pared to the female normal control (NF, n = 50), the
AUC value was measured at 0.678 ± 0.0408, and the cut-
off value at >8.28 ng/ml, with a sensitivity of 54.4% and
a specificity of 77.6%. Taken together, the superiority as
a breast cancer marker, compared to CEA, is attributed
to the higher sensitivity of Trx1 than that of CEA.
Further, the AUC value for CEA in grade I breast car-
cinoma was measured at 0.594 ± 0.0523 with a sensitivityn patients with various cancers
pecificity (%) Criterion (ng/ml) # of serum (Grade)
78.0 >32.3390 197 (I/II/III)
61.0 >29.0533 64 (I/II/III)
81.0 >32.9986 30 (I/II)
73.0 >31.1820 108 (I/II/III/IV)
- - 100 F/M: 50 F / 50 M
Figure 3 Changes in serum Trx1 levels in patients with breast and lung cancers as a function of the progress of the cancers. The
individual mean value (n = 3) was depicted as a scatter dot plot with the median value of each group (horizontal lines) and the interquartile
range (vertical lines). Abbreviations: BC, breast cancer patients; LC, lung cancer patients; I, II, III; divided corresponding cancer (grade I, II, and
III, respectively).
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Trx1 even in grade I breast carcinoma (0.837 ± 0.0399) was
higher than those for CEA in the all cancer grades (I-III). It
is worth noting that the sensitivity for Trx1 (89.4%) is
higher than that for CEA (30.3%), whereas the specificity
for Trx1 (72.0%) is lower than that for CEA (89.8%).
Therefore, a combination of the serum Trx1 and CEA in
patients with breast carcinoma can increase their diagnos-
tic capacity for the early detection of breast cancer.
As depicted in Figure 4, both serum levels of Trx1 and
CEA in breast cancer are elevated as a function of theprogress of breast carcinoma. We plotted the individual
serum levels of Trx1 in 197 breast cancer serums along
the x-axis and that of CEA in the corresponding sample
along the y-axis. Figure 5A displays a good positive correl-
ation between the levels of patients (Pearson r = 0.58971;
P < 0.0001), respectively, suggesting Trx1 sustains the
serum of patients with breast cancer in accordance
with CEA. The false negative group within the box
(region b in Figure 5A) determined by the cut-off value
of CEA (8.28 ng/ml) are rescued from wrong diagnosis
by diagnosing breast cancer with the cut-off value of
Figure 4 Changes of serum Trx1, CEA, and CA15-3 levels in patients breast cancer as a function of the progress of the cancer. The
individual mean value (n = 3) was depicted as a scatter dot plot. The mean value of each group is shown by horizontal lines, and the 95% of
confidence interval (CI) is displayed by vertical lines. Abbreviations: BCL, lobular carcinoma of breast; BCD; ductal carcinoma of breast; NF, normal
female; I, II, III; grade 1, II, III of breast cancer, corresponding cancer grades, respectively. The average data of Trx1, CEA, and CA15-3 levels in sera
were displayed in panels A, B, and C, respectively.
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sitivity of Trx1 (89.8%) compared to that of CEA (54.4%).
The false negative patients determined by both cut-off
values were depicted in region a (16 patients of 197 total
patients: 8.1%).Table 5 Parameters from ROC analysis on serum Trx1, CEA, a
BC Grade AUC* (±SEM) Sensitivity (%) Spec
BC_Total╔ 0.901 ± 0.0252 89.8
0.678 ± 0.0408 54.4
0.179 ± 0.0359 48.6
BC I 0.837 ± 0.0399 89.4
0.594 ± 0.0523 30.3
0.693 ± 0.0482 50.0
BC II 0.908 ± 0.0270 82.9
0.692 ± 0.0478 56.8
0.673 ± 0.0480 44.8
BC III 0.962 ± 0.0156 88.5
0.762 ± 0.0460 66.7
0.794 ± 0.0411 60.6
Normal - -
*P < 0.0001.
**Units of criterion values represent as ng/ml for Trx1 and CEA or U/ml for CA15-3.
╔Upper, middle, and lower values in each row are those for Trx1, CEA, and CA 15–3
§L and D are lobular and ductal carcinoma of breast cancer respectively.Comparison of Trx1 with CA15-3 as a breast cancer marker
It was found that serum from individuals with various car-
cinomas, including breast carcinoma, has higher levels of
CA15-3 than does serum from healthy individuals. CA15-3
is frequently used as a breast cancer marker, but it by itselfnd CA15-3 levels in patients with breast cancer
ificity (%) Criterion** Value # of serum (# of L:-D) §
78.0 >32.1725 197 (106:91)
77.6 >8.28
89.8 >29.8227
72.0 - 66 (35:31)
89.8 -
83.7 -
86.0 - 70 (37:33)
77.6 -
89.8 -
92.0 - 61 (34:27)
77.6 -
89.8 -
- - 50 (NF)
, respectively.
Figure 5 Correlation between serum markers for breast cancer. A denotes the correlation between the serum Trx1 and CEA levels in
patients with breast cancer (BC); B, the correlation between the serum Trx1 and CA15-3 levels in breast cancerous females; C, the correlation
between the serum CEA and CA15-3 levels in patients with breast cancer. Vertical and horizontal solid lines indicate the cut-off values for corresponding
marker for breast cancer. The individual values are the average values of three (for Trx1 and CEA) or two (for CA15-3) measurements.
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cancer, mainly due to its lack of sensitivity [22]. Therefore,
we comparatively investigated the diagnostic capacities of
Trx1 and CA15-3 for the detection of breast cancer and
compared their parameters from respective ROC curve
analysis.
As shown in Figure 4B, increased serum level of CA15-
3 was detected in breast cancer patient (∼58%, from
21.92 ± 7.854 U/ml to 34.68 ± 24.14 U/ml; mean ± SD).
Serum CA15-3 levels were observed to have a propor-
tional correlation with the progress of breast cancer,
but they exhibited a less correlation with the progress
of breast cancer (P < 0.05, from one-way ANOVA ana-
lysis) compared with Trx1 (P < 0.0001).
To compare the utility of CA15-3 and Trx1 as blood
markers for breast cancer, the serum CA15-3 levels for
breast cancer were subjected to ROC curve analysis, and
the results are shown in Table 5. For CA15-3, when com-
pared to the female normal control, the AUC value was
measured at 0.719 ± 0.0359 with a sensitivity of 48.6% and
a specificity of 89.8%. Further, the AUC value for CA15-3
in the early-stage (stage I) breast carcinoma was measured
at 0.693 ± 0.0482 with a sensitivity of 50.0% and a specifi-
city of 83.7%. The AUC value for Trx1 even in the stage I
breast carcinoma (0.837 ± 0.0399) was higher than that for
CA15-3 in the corresponding cancer stage (0.691 ±
0.0482). The sensitivity for Trx1 (89.8%) is much higher
than that for CA15-3 (48.6%), whereas the specificity for
Trx1 (78.0%) is lower than that for CA15-3 (89.8%). There-
fore, a combination of the serum Trx1 and CA15-3 levels
in patients with breast cancer could improve the diagnostic
sensitivity of CA15-3 for detection of breast cancer.
As depicted in Figure 4A and 4C, both serum levels of
Trx1 and CA15-3 in breast cancer are elevated comparedto corresponding control. We plotted the levels of Trx1
in 197 individual breast cancer serums along the x-axis
and of CA15-3 in the corresponding sample along the
y-axis. Figure 5B shows no correlation between the patients
(Pearson r = 0.08189; P = 0.2526), suggesting Trx1 is sus-
tained in the serum of patients with breast cancer in a
quite different manner from CA15-3 and also supporting
Trx1 as an complementary and thus effective companion
marker to CA15-3. The false negative patients within the
box (region b in Figure 5B) determined by the cut-off
value of CA15-3 (29.8227 U/mL) are rescued from the
wrong diagnosis by diagnosing breast cancer with the
cut-off value of Trx1 (32.1725 ng/mL), due to the higher
sensitivity of Trx1 (89.8%) compared to CA15-3 (48.6%).
The false negative patients determined by both cut-off
values were depicted in region a (6 patients of 197 total
patients: 3%).
The false negative patients (38 patients of 197 total pa-
tients; 19.3%) determined by both cut-off values of
CA15-3 (29.8227 U/mL) and CEA (8.28 ng/mL) were
depicted in region “a” shown in Figure 5C. Figure 5C
showed no correlation between the patients (Pearson
r = 0.02728; P = 0.7029), suggesting both markers are
sustained in the serum of patients with breast cancer
in quite different manners and suggesting the com-
bined use of CEA with CA15-3 is effective for screening
the patients with breast cancer.
Taken together, we suggest that the Trx1 blood test it-
self is reliable for diagnosing breast cancer or as a
screening test for early detection of breast cancer, and
moreover that the combinational use of Trx1 with ei-
ther CEA or CA15-3 overcomes their problems (poor
sensitivity) encountered in diagnosis by the CEA or CA15-
3 test alone.
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The measurement of serum levels of Trx1 was per-
formed on the sera of 197 breast cancer patients over a
wide range of ages with a uniform distribution (48.5 ±
18.43; mean ± SD). The individual data were depicted as
a function of age. As shown in Figure 6A, the serum
levels appear to be slightly decreased as the function of
age (slope = −0.032 ± 0.0348), but they showed no statis-
tical significance (P = 0.3605).
As shown in Figure 6B, the Trx1 level in the patients
over 50 (40.44 ± 6.791 for age ≥50; mean ± SD) was not sig-
nificantly different from that in the patients below 50
(41.05 ± 7.078 for age <50) (P = 0.5587). The level in the
menopausal and post-menopausal patients (41.49 ± 6.0171,
n = 66) was not significantly different from that in the pre-
menopausal patients (41.55 ± 5.610, n = 40) (P = 0.9545).
Discussion
In the previous study, the expression levels of Trx1 in
human normal tissue and cancerous tissue were exam-
ined [21]. Trx1 was found to be expressed at the lowest
level in normal breast tissue among 48 different normal
human tissues, and at a higher level in breast cancer
tissue than in other cancerous tissue, as measured by
qRT-PCR and Western blotting. In addition, the more
progressed the cancer is, the higher the induction fold
of mRNA expression of Trx1. Thus, the induction fold
of mRNA expression of Trx1 becomes high in stage II-IV
breast cancer, particularly stage IV breast cancer, that is,Figure 6 Relationship of serum Trx1 levels in patients with breast can
patients with breast cancer was provided by the supplier. The individual va
no relationship between serum level of Trx1 and age of breast cancer patie
menopause status of patient with breast cancer.metastatic breast cancer. Further, the induction fold of
mRNA expression of Trx1 is closely associated with the
malignancy of cancer as it increases with the progression
of cancer. Therefore, the induction fold of mRNA expres-
sion of Trx1 is associated with subdivision of cancer
stages. Found to be overexpressed in human breast cancer
tissues, as described above, Trx1 allows the diagnosis and
prognosis of breast cancer and thus is useful as a diagnos-
tic marker for breast cancer.
The present study provides a diagnostic marker for
breast cancer, comprising the Trx1 level in blood. Breast
cancer patients were found to have significantly higher
serum Trx1 levels than normal persons, as measured by
an indirect ELISA. In addition, comparison between
breast cancer and other cancers showed that signifi-
cantly high Trx1 levels were detected in blood taken
from breast cancer patients, compared to patients with
other cancers. Moreover, the serum Trx1 level exhibited
a proportional correlation with the progress of breast
cancer. Analysis of serum Trx1 level in normal female
and patients with breast cancer as function of age revels
that the level in female control seems to increase as a
function of age (P = 0.0848) (Figure 1B) indicating a
weaker association with the age, but the patient level
does not response to increase of age (P = 0.3605)
(Figure 6A). The slight increase of serum Trx1 level
in normal female in older female control could be due
to the oxidative stress increased with age. No rela-
tionship of Trx1 levels in the patients with their ages
suggests that significant elevation of the trx1 levelscer with age and status of menopause. Clinical information for
lues are the average values of three measurements. Panel A denotes
nt. Panel B shows no relationship between serum level of Trx1 and
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We also analyzed data from the pre-menopausal and
post-menopausal patients. As shown in Figure 6B, the
status of menopause is not associated with the level of
Trx1 in patients with breast cancer (P = 0.9545). Taken
together, these results indicate that there are no signifi-
cant relationships between the Trx1 level and meno-
pause status of the patients. Based on the observation,
we suggest that age and menopausal status do not act as
considerable factor to affect serum Trx1 level regardless
of the presence or absence of breast cancer although age
and menopausal status are well established risk factor
for breast cancer [22].
Carcinoembryonic antigen (CEA) was first identified
in 1965 by Phil Gold and Samuel O. Freedman in human
colon cancer tissue extracts [23]. CEA is a glycoprotein
involved in cell adhesion [24]. It is normally produced
during fetal development, but the production of CEA
stops before birth. Therefore, it is not usually present in
the blood of healthy adults, although levels are raised in
heavy smokers. It was found that serum from individuals
with colorectal carcinoma, gastric carcinoma, pancreatic
carcinoma, lung carcinoma and breast carcinoma, as
well as individuals with medullary thyroid carcinoma,
had higher levels of CEA than healthy individuals
[25-27]. Analysis of detection of CEA in breast cancer
patients leads to that the CEA blood test is not reliable
for diagnosing breast cancer or as a screening test for
early detection of the cancer especially due to the lack of
sensitivity (54.4% for all grades of the cancer from I to
III, 30.3% for the grade I) (Figure 4B and Table 5). If the
test is not sensitive, then it may miss cancers. Therefore,
the CEA breast cancer screening tests miss a large num-
ber of patients with breast cancer depicted in Figure 5B.
This wrong diagnosis becomes severer in the early-
phased patients (grade I) with a sensitivity of 30.3%
(Table 5).
Cancer antigen (CA) 15–3 is a circulating MUC-1
antigen in peripheral blood that is a normal product of
breast tissue, and it does not cause breast cancer. One of
the widely used tumor marker in breast cancer is CA15-
3, but it is not sensitive or specific enough to be consid-
ered useful as a tool for cancer screening. Its main use is
to monitor a person's response to breast cancer treat-
ment in case of the cancer that overproduces CA15-3
and to help watch for breast cancer recurrence. The
present data also indicate that the CA15-3 blood test on
breast cancer patients is not reliable for diagnosing
breast cancer or as a screening test for early detection of
the cancer due to its lack of sensitivity. The breast can-
cer screening test by CA15-3 misses a large number of
breast cancer patients. This wrong diagnosis becomes
more severe in the early-phase patients, with a sensitivityof only 50.0% and 44.8% for the stage I and stage II, re-
spectively (Table 5).
In breast cancer as well as in other solid tumors all
tumor markers actually available are not tumor specific.
There are some reports concerning serum breast cancer
markers such as CEA, and CA15-3, and class I alcohol
dehydrogenase (ADH). Among all tested classes of ADH
isoforms, only class I had higher activity in the serum of
patients with breast cancer in stage IV [28,29]. However,
most of breast cancer markers show lack of the diagnos-
tic sensitivity and specificity.
In a combination analysis we investigated the diagnostic
capacity of Trx1 and CEA for the detection of breast can-
cer comparing the use of fixed cut off values. On this
combination analysis we reached a sensitivity of 90.9% for
both markers (Figure 5A). Considering the sensitivity
(54.4%) in all stages of breast cancer for CEA alone, this
combination analysis with Trx1 is helpful to rescue 36.5%
of patients with breast cancer from wrong diagnosis.
In another combined analysis, we investigated the diag-
nostic capacity of Trx1 and CA15-3 for the early detection
of breast cancer, comparing the use of fixed cut-off values.
In this combination analysis, shown in Figure 5B, we
reached a sensitivity of 97.0% for both markers. Consider-
ing the sensitivity of CA15-3 (48.6%) alone, this combin-
ation analysis with Trx1 could help rescue 48.4% of
patients with breast cancer from the wrong diagnosis.
Finally, we examined the diagnostic capacity of CEA
and CA15-3 as the combinational markers for patients
with breast cancer. This combination analysis also sig-
nificantly increases sensitivity for both markers com-
pared to the individual sensitivity for CEA and CA15-3
(a sensitivity of 48.6% for CEA alone, 48.6% for CA15-3
alone, and 80.7% for both markers) (Figure 5C).
In summary, considering the sensitivities derived from
each of three sets of combinational analyses, the set of
Trx1 and CA15-3 is the most efficient combination for
the detection of the patients with breast cancer among
three sets of combination (a sensitivity of 97.0% for a set
of Trx1 and CA15-3, 91.9% for a set of Trx1 and CEA,
and 80.7% for set of CEA and CA15-3). Comparison of
Trx1 with CEA or CA15-3 as a serum breast cancer
marker suggests that Trx1 is the most superior marker
for breast cancer.
Conclusions
Comparison of breast cancer with other cancers showed
that the highest Trx1 levels with its high sensitivity and
specificity were detected in blood taken from breast can-
cer patients, compared to patients with other cancers
and normal persons. Moreover, the serum Trx1 level ex-
hibited a proportional correlation with the progress of
breast cancer. Taken together, we conclude that serum
Trx1 is the most useful marker for the prognosis and
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http://www.biomedcentral.com/1756-0500/7/7early diagnosis of breast cancer. In addition, we suggest
that the diagnostic capacity of CEA or CA15-3 alone for
the early detection of breast cancer, especially regarding
sensitivity, would be significantly improved by its com-
bination with Trx1.
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